Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04MQZ
|
|||
| Drug Name |
PMID26560530-Compound-7
|
|||
| Drug Type |
Small molecular drug
|
|||
| Company |
Merck & Co., Inc
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C10H8N2O2
|
|||
| Canonical SMILES |
C1=CC=C2C(=C1)NC(=N2)C=CC(=O)O
|
|||
| InChI |
1S/C10H8N2O2/c13-10(14)6-5-9-11-7-3-1-2-4-8(7)12-9/h1-6H,(H,11,12)(H,13,14)/b6-5+
|
|||
| InChIKey |
FEGNPBYZFFAMCR-AATRIKPKSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Tissue transglutaminase (TG2) | Target Info | Inhibitor | [1] |
| Target's Patent Info | Tissue transglutaminase (TG2) | Target's Patent Info | [1] | |
| KEGG Pathway | Huntington's disease | |||
| Pathway Interaction Database | Beta1 integrin cell surface interactions | |||
| Thromboxane A2 receptor signaling | ||||
| Alpha9 beta1 integrin signaling events | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.